Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
ENSG00000306538 is a long noncoding RNA (lncRNA) gene, described as a "novel transcript, antisense to ARHGAP35." This means the RNA transcript is produced from the strand of DNA opposite to that encoding the ARHGAP35 gene, and is categorized as an antisense lncRNA; by definition this does not encode a protein and is not a classical therapeutic target. There are no reports of this specific transcript having a defined function, disease association, biomarker status, or relevance to current therapeutic interventions. The name is generic and may encompass multiple transcript variants, lacking specificity or detailed annotation in established databases[3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Novel transcript, antisense to ARHGAP35.